Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

Belimumab, a fully human monoclonal antibody binding soluble BAFF, is currently FDA-approved for systemic lupus erythematosus. There are several studies on belimumab in IIM, reporting the highest ...

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.